Company intelligence / Profile preview

MicroVascular Tissues

San Diego, California, United Statesmvtissues.com ↗

Ownership: Private
Development stage: Commercial

Overview

MicroVascular Tissues has commercialized mVASC®, an allogeneic human tissue allograft derived from microvascular extracellular matrix. Clinical results from the HIFLO Trial demonstrated that mVASC significantly improved healing rates and peripheral neuropathy in nonhealing diabetic foot ulcers compared to standard care. The product is now covered by major insurers for this indication.

Therapeutic areas: EndocrinologyDermatology
Modalities: Allogeneic tissue graftExtracellular matrix therapyBiologic (human cadaver-derived ECM)
Industry: Biotech

Drug pipeline

1 asset

mVASC

Commercial

Indications: Diabetic foot ulcers, Peripheral neuropathy

Partnerships

Anthem Blue Cross Blue Shield (payer coverage)Amerigroup (payer coverage)

Beyond the preview

Go deeper on MicroVascular Tissues.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroVascular Tissues.

Explore the full profile